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Bharat Thyagarajan,1 Bruce Lindgren,2 Saonli Basu,3 Sriharsha Nagaraj,4 Myron D. Gross,1
Daniel J. Weisdorf,4 Mukta Arora4Alkylating agents with or without ionizing radiation are frequently used in pretransplant conditioning regi-
mens. Damage induced by these agents is commonly repaired by the base excision repair (BER) pathway.
Hence, we hypothesized that genetic polymorphisms in the BER pathway will be associated with posthema-
topoietic cell transplant (HCT) outcomes.We evaluated the association between single nucleotide polymor-
phisms (SNPs) (n 5 179) in the BER pathway with treatment-related mortality (TRM) at 1 year and disease
relapse in a cohort of 470 recipients who underwent allogeneic HCT for treatment of hematologic malignan-
cies at the University of Minnesota. After adjustment for age at transplant, donor type, race, and conditioning
regimen, 4 SNPs inOGGI, LIG3, andMUTYH genes (rs159153, rs3135974, rs3219463, and rs3219476) were
associated with increased risk of TRM, whereas 2 SNPs in the TDG gene (rs167715 and rs2374327) were
associated with decreased risk of TRM at 1 year (P # .01). Patients with increasing numbers of deleterious
alleles in the BER pathway showed a higher cumulative incidence of TRM at 1 year (51% for $4 deleterious
alleles versus 14% for#1 deleterious allele; P\.001). One SNP, rs3135974, in the LIG3 gene, was associated
with decreased risk of disease relapse (P\ .001) post-HCT. These findings suggest that SNPs in the BER
pathway can be used as genetic biomarkers to predict individuals at high risk for TRM and disease relapse.
Modulation of pretransplant conditioning may alter risk in these patients.
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Despite rapid advances in hematopoietic cell trans-
plant (HCT) techniques, the procedure continues to
be associated with a high morbidity and mortality,
with treatment-related mortality (TRM) ranging
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6/j.bbmt.2010.03.001survive the acute toxicity, disease relapse remains
a major cause of death [3]. High doses of ionizing radi-
ation and alkylating agents such as cyclophosphamide
and melphalan, induce significant DNA damage [4]
and are commonly used duringHCT [3]. Single nucle-
otide polymorphisms (SNPs) in DNA repair genes
may potentially influence the effectiveness of various
chemotherapeutic regimens used in HCT, and have
been associated with treatment outcomes and overall
survival (OS) in patients undergoing chemotherapy
for a variety of hematologic malignancies [5,6]. One
study has also shown an association between 2
polymorphisms in the DNA repair genes and OS in
patients undergoing autologous transplants for
treatment of multiple myeloma [7].
The base excision repair (BER) pathway is the pri-
mary DNA repair pathway that corrects base lesions
that arise because of oxidative, alkylation, deamination,
and depurination/depyrimidination damage [8], and
plays an important role in repairing the damage caused
by ionizing radiation and chemotherapeutic agents [4].
There are at least 8 specialized DNA damage proteins
that recognize specific types of DNA damage, which
Biol Blood Marrow Transplant 16:1084-1089, 2010 1085DNA Repair SNPs and Outcomes after Allogeneic HCTcreate abasic or apurinic/apyrimidinic (AP) sites [9,10].
TheDNA at the AP site is incised by an AP lyase (DNA
polymerase beta), and repair of a single nucleotide is
completed by DNA ligase III (short patch repair
pathway) [8]. Alternatively, the DNA at the AP site
can be cleaved by anAP endonuclease (APEX1), and re-
pair proceeds via a PCNA-dependent manner; repair of
2 or more nucleotides is completed by DNA ligase I
(long patch repair pathway) [8].
No study has yet systematically evaluated the asso-
ciation between SNPs in the BER pathway and out-
comes after allogeneic HCT. We evaluated the
association between SNPs in the BER pathway,
TRM at 1 year, and disease relapse in a cohort of
patients who received an allogeneic HCT for hemato-
logic malignancy at the University of Minnesota. We
hypothesized that SNPs in BER genes would be
independently associated with TRM at 1 year and
disease relapse.MATERIALS AND METHODS
Patient Selection
All patients (pediatric and adult) who underwent an
allogeneic HCT from an HLA-identical sibling donor,
matchedormismatchedunrelated donor (URD), or sin-
gleumbilical cordblood (UCB) transplant for treatment
of hematologic malignancies from January 1, 1998, to
December 31, 2007, were eligible for study (n 5 587).
All patients received a conditioning regimen that in-
cluded an alkylating agent (eg, cyclophosphamide)
and/or ionizing radiation. After excluding patients for
whom DNA samples were not available, 480 (82%)
patients were included in this study. This study was
approved by the institutional review board at the
University of Minnesota and a waiver of informed con-
sent from individual patientswas obtained for this study.Clinical Data and Collection of DNA Samples
All clinical data was obtained using the University
of Minnesota Blood andMarrow Transplant Database
and supplemented by chart reviews where necessary.
Demographic and transplant characteristics, which in-
cluded patient and donor age at transplant, patient and
donor sex, type of donor (related, URD, or UCB),
graft source (bone marrow versus peripheral blood
stem cell [PBSC] versus CB), race, patient’s underlying
disease, disease status at transplant, HLA matching
between donor and recipient, conditioning intensity
(myeloablative [MA] or reduced-intensity), condition-
ing regimen used for transplant, graft-versus-host dis-
ease (GVHD) prophylaxis, cytomegalovirus (CMV)
serologic status of recipient and donor prior to trans-
plant, and survival at time of last follow-up were
collected. HLA-matching status for URD transplantswas categorized as well matched, partially matched,
or mismatched based on classification proposed by
Weisdorf et al. [11]. HLA-matching status for CB
transplants was based on antigen level HLA-A, B,
and allele level HLA-DRB1 typing.
TRMwas defined as mortality because of all causes
other than disease relapse or progression. Causes of
death were carefully evaluated only to exclude patients
with accidental death unrelated to HCT (n 5 1). Dis-
ease relapse or progression was defined by first
evidence of hematologic, cytogenetic, molecular, or
radiologic evidence of relapse or progression of the
malignancy.
DNA samples from patients were obtained from
PB samples collected prior to HCT. All patients with
acute leukemias had no evidence of leukemic blasts
in peripheral blood at the time of obtaining blood for
DNA extraction. DNA was extracted from buffy coat
using either the Puregene DNA extraction method
(for samples collected prior to 2001) (Gentra Systems,
Minneapolis, MN) or the Qiagen Mini Blood kit (all
samples collected during or after 2001) (Qiagen Inc.,
San Jose, CA) as per manufacturer recommendations.
All DNA samples were collected and stored at 4C in
the Molecular Diagnostics Laboratory at the Univer-
sity of Minnesota Medical Center, Fairview, prior to
use in the study.
SNP Selection and Genotyping
Weuseddata fromEnvironmentalGenomeProject
[10,12] to identify and select linkage disequilibrium
(LD) tagSNPs that had a frequency of $5% in
the Caucasian population in 27 BER genes. If genes
did not have tagSNPs information in the
Environmental Genome Project, we used HapMap
data for Caucasian populations to identify tagSNPs
that had $5% frequency in Caucasian populations
using the Genome Variation Server software (http://
gvs.gs.washington.edu/GVS/). We then supplemented
this list with nonsynonymous SNPs that were
identified to be functionally important using 3
software programs: PolyPhen [13], SIFT [14], and
SNP3D [15]. This approach allowed us to select 263
SNPs (210 tagSNPs and 53 SNPs that may be func-
tionally important) in 27 genes with known function
in the BER pathway. All DNA samples were genotyped
using the Sequenom iPLEX system at the Biomedical
Genomics Center at the University of Minnesota. All
primers and probes were designed using Sequenom
primer design software. We were able to design
primers and probes for 239 SNPs.
Statistical Analysis
All statistical analyses were performed using SAS
software version 9.1 (SAS Institute, Inc., Cary, NC)
and R Statistical software version 2.4.1 (http://cran.
Table 1. Demographic and Transplant Characteristics of
Patients Who Underwent Allogeneic Hematopoietic Stem
Cell Transplant at the University of Minnesota: 1998-2007
Variable N (%)
N 470 (100)
Recipient age at transplant (years)
<20 133 (28)
21-40 109 (23)
>40 228 (49)
Median age (range), years 35.7 (0.7-69.8)
Donor age at transplant (years)
<20 113 (24)
21-40 121 (25)
>40 195 (42)
Not known 41 (9)
Median age (range), years 37.7 (0.3-71.7)
Race
African American 14 (3)
Asian 18 (4)
Caucasian 404 (86)
Hispanic 13 (3)
Native American 4 (1)
Unknown 10 (2)
Mixed 7 (1)
Diagnosis
Acute lymphoid leukemia 92 (20)
Acute myeloid leukemia 151 (31)
Chronic myeloid leukemia 73 (16)
Lymphoma 78 (16)
Myelodysplastic syndrome 40 (9)
Others 36 (8)
Disease status at transplant
Complete response 288 (62)
Partial response 24 (5)
Relapse/primary induction failure 118 (25)
Myelodysplastic syndrome 38 (8)
Missing 2 (<1)
CMV Serological status
Recipient positive/donor positive 101 (22)
Recipient positive/donor negative 146 (31)
Recipient negative/donor positive 62 (13)
Recipient negative/donor negative 161 (34)
Conditioning
Myeloablative 378 (80)
Reduced intensity 92 (20)
Donor type
Sibling 296 (63)
Unrelated donor 75 (16)
Cord blood 99 (21)
Stem cell source
Marrow 145 (31)
PBSC 226 (48)
Cord blood 99 (21)
GVHD prophylaxis
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cies (MAF), Hardy Weinberg proportions, and LD
among SNPs genotyped were estimated. Assuming an
additive model for the SNPs, the association between
each of these SNPs and TRM at 1 year was evaluated
using a proportional hazardsmodel with disease relapse
as the competing risk as described byFine andGray [17]
after adjustment for covariates. Covariates included
age at transplant as a continuous variable, race, type of
donor (sibling, URD or UCB), and conditioning regi-
men (MA or reduced-intensity). Other covariates such
as clinical diagnosis, disease status at transplant, sex
mismatch, and CMV status at time of transplant were
neither independent predictors of TRM at 1 year in
this dataset nor did they significantly change the
observed associations between SNPs and TRM at 1
year and were excluded from the final model. A value
ofP# .01was considered tobe significant for this study,
and individual SNPs that were significant were evalu-
ated in a backward stepwise regression model after
adjustment for clinical covariates. Only SNPs that
remained significantly associatedwithTRMin themul-
tivariate model were combined to create an ‘‘SNP
score’’ in which each individual received a point for
each allele associated with increased incidence of
TRM (ie, ‘‘deleterious alleles’’). We then evaluated
the association between the SNP score and cumulative
incidence (CI) of TRM at 1 year using the Fine and
Gray proportional hazardsmodel with competing risks.
Cumulative incidence estimates were calculated for
TRM with disease relapse as the competing risk. Inci-
dence of TRM at 1 year was plotted by categories of
the SNP score. Gray’s test [18] was used to compare
the incidence rates across time by categories of the
SNP score.
We also evaluated the association between BER
SNPs and disease relapse where TRM was used as
the competing risk for disease relapse using methods
described above. Covariates considered when evaluat-
ing the association between SNPs and disease relapse
included age at transplant, race, disease status at trans-
plant, clinical diagnosis, and conditioning regimen.CsA/MMF 125 (27)
CsA/MTX 244 (52)
T cell depletion 43 (9)
Other 58 (12)
Acute GVHD
No AGVHD 234 (50)
Grade I 49 (10)
Grade II 121 (26)
Grade III/IV 66 (14)
Chronic GVHD 145 (31)
Follow-up in years (survivors), median (range) 3.3 (0.9-8.6)
CMV indicates cytomegalovirus; PBSC, peripheral blood stem cell; CsA,
cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate;
GVHD, graft-versus-host disease.RESULTS
Thebaseline characteristics of the studypopulation
are described in Table 1. Briefly, a majority of the
patients underwent MA HCT from an HLA-identical
sibling donor (n 5 231), 72% of the cohort were
$21years at the time of transplant, and 86% of the
cohort were Caucasian. Acute leukemia (acute myelog-
enous leukemia and acute lymphoid leukemia) (52%)
was the most common diagnosis. Among 75 URD
recipients, 27 (36%) of recipients received a transplant
from a well-matched donor, 36 (48%) from a partially
matched donor, and 10 (13%) from a mismatcheddonor. Insufficient data was available to categorize 2
patients. Among 99 UCB recipients, 47% were mis-
matched at a single locus (5/6), 43% were mismatched
Table 2. Association between Individual SNPs in BER Genes and 1-Year Transplant-Related Mortality after Hematopoietic Cell
Transplant: Univariate Analysis of Each SNPAdjusted for Clinical Covariates
SNPs Gene (Location within Gene) Alleles Minor Allele Frequency
Hazard Ratio (95% CI); P-Value
Entire Cohort* (n 5 470)
†Myeloablative Transplants with
Sibling Donors† (n 5 231)
rs159153 OGG1 (50 region near gene) T/C 0.33 1.41 (1.08, 1.85); P 5 .013 1.28 (0.87, 1.89); P 5 .211
rs167715 TDG (intron 2) T/C 0.10 0.44 (0.25, 0.78); P 5 .004 0.34 (0.14, 0.81); P 5 .015
rs2374327 TDG (intron 1) A/T 0.25 0.62 (0.45, 0.87); P 5 .006 0.65 (0.42, 1.01); P 5 .053
rs3135974 LIG3 (intron 3) G/A 0.10 1.80 (1.24, 2.59); P 5 .002 1.63 (0.98, 2.73); P5 .061
rs3219463 MUTYH (30 noncoding region) G/A 0.26 1.62 (1.24, 2.13); P < .001 1.88 (1.35, 2.62); P < .001
rs3219476 MUTYH (30 noncoding region) G/T 0.34 1.66 (1.26, 2.18); P < .001 1.70 (1.19, 2.44); P 5 .004
SNP indicates single nucleotide polymorphism; CI, confidence interval.
Shown are SNPs significant at P # .01 level in univariate analysis in the entire cohort.
*This model was adjusted for age at transplant, race, type of donor, and conditioning regimen.
†Restricted to patients who underwent myeloablative transplants from sibling donors.
Table 3. Association between Individual SNPs in BER Genes
and 1-Year Transplant-Related Mortality after Hematopoietic
Cell Transplant: Multiple Regression Analysis
Variables
Hazard Ratio (95% CI);
P-Value Entire Cohort
(n 5 454)
rs167715 0.44 (0.25, 0.78); P 5 .005
rs3135974 1.79 (1.24, 2.60); P 5 .002
rs3219463 1.78 (1.35, 2.36); P < .001
Age at transplant 1.05 (1.03,1.06); P < .001
Donor type
Sibling (reference) 1.00
Unrelated 1.97 (1.21, 3.18); P 5 .006
Cord blood 2.06 (1.20, 3.55); P 5 .009
Reduced intensity conditioning 0.32 (0.18, 0.55); P < .001
Caucasian race 1.25 (0.72, 2.17); P 5 .419
CI indicates confidence interval; SNP, single nucleotide polymorphism;
BER, base excision repair.
None of the gene-gene interactions were significant (all P > .3).
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plant. Cumulative incidence of TRM at 1 year was
25% (95%CI21%-29%) and the cumulative incidence
of disease relapse/progression at 2 years was 26% (95%
CI 22%-30%).
Genotypes for these candidate SNPs were avail-
able on 98% (n 5 470) of all patients for whom
DNA was available (n 5 480). Among SNPs that
were successfully genotyped (n 5 179) 80% were
tagSNPs (n5 143) and 20% were functionally impor-
tant SNPs (n 5 36). Among SNPs that could not be
genotyped (n 5 60) 85% were tagSNPs (n 5 51) and
15% were functionally important SNPs (n 5 9).
Poor completion rates (\80%) was the most common
reason for inability to genotype SNPs (n 5 57),
whereas genotypes for 3 SNPs were not analyzed
because of poor concordance (\95%) in blinded
duplicate samples. Detailed description of biological
function of genes, number of SNPs genotyped within
individual genes, and number of samples genotyped
is given in online supplement 1.
Association between BER SNPs and 1-Year TRM
After adjustment for age at transplant, donor type,
race, and conditioning regimen, 6 SNPs (rs159153,
rs167715, rs2374327, rs3135974, rs3219463, and
rs3219476) were associated with 1-year TRM (P #
.01) (Table 2). Three of these SNPs (rs167715,
rs3219463, and 3219476) remained significantly asso-
ciated with TRM when the analyses were restricted to
a more homogeneous cohort of patients who under-
went MA allogeneic sibling transplants (Table 2). In
multiple regression analysis of the entire cohort, 3
SNPs (rs167715, rs3135974, and rs3219463) remained
significantly and independently associated with 1-year
TRM (P # .01) after adjustment for other SNPs and
clinical covariates (Table 3). There were no significant
gene-gene interactions (all P . 0.3). These 3 SNPs
were combined to create the ‘‘SNP score’’ variable
where each individual received 1 point for alleles that
increased TRM risk in any of the 3 SNPs (rs167715,
rs3135974, and rs3219463). Thus, individuals received0 points if they had the T/T genotype for rs167715 or
G/G genotype for SNPs rs3135974, and rs3219463, 1
point if they had T/C genotype for rs167715 or G/A
genotype for SNPs rs3135974 and rs3219463, and 2
points if they had the C/C genotype for rs167715 or
A/A genotype for SNPs rs3135974 and rs3219463.
Thus, the minimum SNP score for any given individ-
ual could be 0 and themaximum SNP score could be 6.
In this study, there were no individuals who were
homozygous mutant for all 3 SNPs, and hence, the
SNP score ranged from 0 to 5. The SNP score was
found to be positively associated with 1 year TRM
(hazard ratio [HR], 95% CI: 1.84 [1.50, 2.25];
P \ .001). The cumulative incidence of TRM at 1
year for patients with SNP score of $4 was 51%
(95% CI: 37%-65%) compared to 14% (95%
CI:4%-24%) for those with SNP score #1 (P \
.001) (Figure 1). None of the interactions between
the SNP score and the clinical covariates were statisti-
cally significant (all P . .1).
Association between BER SNPs and Disease
Relapse
After adjustment for age at transplant, race, disease
status at transplant, diagnosis, and conditioning
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Figure 1. Cumulative incidence estimates for treatment-related mor-
tality (TRM) according to different categories of SNP score (P\.001).
Disease relapse was used as the competing risk in this model. The
SNPs rs167715, rs3135974, and rs3219463 were used to create the
SNP score variable. Each individual received 1 point for each allele asso-
ciated with increased incidence of TRM (ie, ‘‘deleterious alleles’’). Be-
cause the mutant alleles for SNPs rs3135974 (A allele) and rs3219463
(A allele) were associated with increased TRM risk, individuals received
0 points for being homozygous for the wild-type allele (ie, G/G geno-
type), 1 point for being heterozygous (ie, G/A genotype), and 2 points
for being homozygous for the mutant allele (ie, A/A genotype) for each
of these SNPs. Because the mutant allele for rs167715 was associated
with decreasedTRMrisk, individuals received 2points if they had the nor-
mal genotype (ie, T/T genotype), 1 point for being heterozygous (ie, T/C
genotype), and 0 points for being homozygous for the mutant allele for
rs167715 (ie, C/C genotype).
1088 Biol Blood Marrow Transplant 16:1084-1089, 2010B. Thyagarajan et al.regimen, the GA genotype for rs3135974 in the LIG3
gene was significantly associated with reduced risk
of disease relapse (HR [95% CI]: 0.39 [0.22, 0.69];
P 5 .001) compared to the GG genotype. The cumu-
lative incidence of disease relapse at 2 years was 29%
(95% CI: 24%-34%) for those with the GG genotype
compared to 15% (95% CI: 7%-23%) with the G/A
genotype, whereas there was no disease relapse (0%)
among those with the A/A genotype (P 5 .007)
(Figure 2). The results were similar when the analyses
were restricted to patients who underwent an MA0.0
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Figure 2. Cumulative incidence estimates for disease relapse accord-
ing to rs3135974 (P 5 .007). Treatment-related mortality was used as
the competing risk in this model.transplant from a sibling donor (HR [95% CI]: 0.43
[0.19, 0.99]; P 5 .047). There were no significant
gene-clinical covariate interactions (all P. .1). Specif-
ically, there was no interaction between clinical factors
such as disease status, diagnosis, conditioning regi-
men, recipient age at transplant; potential risk factors
for disease relapse; and rs3135974 (P . .1).DISCUSSION
This study found 6 SNPs in 4 BER genes to be
individually associated with 1-year TRM and 1 SNP
to be associated with disease relapse among patients
undergoing allogeneic HCT after adjustment for
clinical covariates. We also showed that increasing
numbers of deleterious alleles in the BER pathway
led to a higher cumulative incidence of 1-year TRM.
Previous studies in nontransplant populations did
not find an association between specific SNPs in
BERgenes (rs3136820 in APEX1 gene and rs25487,
rs25489, and rs1799782 in XRCC1) and treatment
response to AML or NHL [5,6]. One previous
report examining patients undergoing autologous
transplantation for multiple myeloma evaluated 4
SNPs in 3 DNA repair genes (related to the
nucleotide excision repair and double strand DNA
repair pathway) and found a significant association
between 1 SNP in ERCC2 (rs13181), 1 SNP in
XRCC3 (rs861539), and median time to treatment
failure, but not overall survival [7]. However, this
study did not evaluate any of the SNPs evaluated in
the present study [7].
This is the first study to evaluate the role of BER in
predicting treatment response after allogeneic HCT.
Five of the 6 SNPs associated with TRM were located
in 3 DNA damage recognition genes (OGG1, MU-
TYH, and TDG), indicating that variation in recogni-
tion ofDNAdamagemay be an important determinant
of the DNA repair response. The 8-oxoguanine DNA
glycosylase (OGG1) and mutY homolog (MUTYH)
both encode enzymes involved in oxidative DNA dam-
age repair [19]. The OGG1 gene is responsible for the
excision of 8-oxoguanine, a mutagenic base byproduct
that occurs as a result of exposure to reactive oxygen
[19,20]. The SNP, rs159153, in the OGG1 gene is
located in the 50 region of the gene upstream from
the known promoter regions for this gene. The mutY
homolog (MUTYH) gene excises adenine bases
from the DNA backbone at sites where adenine is
inappropriately paired with guanine, cytosine, or
8-oxo-7, 8-dihydroguanine, a major oxidatively
damaged DNA lesion [19,20]. Both SNPs, rs3219463
and rs3219476, are located in the noncoding 30
region of the MUTYH gene. The thymine-DNA gly-
cosylase (TDG) removes thymine moieties from G/T
mismatches, C/T and T/Tmispairings by hydrolyzing
the carbon-nitrogenbondbetween the sugar-phosphate
Biol Blood Marrow Transplant 16:1084-1089, 2010 1089DNA Repair SNPs and Outcomes after Allogeneic HCTbackbone ofDNAand themispaired thymine [21].This
enzyme plays a central role in cellular defense against
genetic mutation caused by the spontaneous deamina-
tion of 5-methylcytosine and cytosine [21]. Both
SNPs, rs167715 and rs2374327, are located in intronic
regions (introns 2 and 1, respectively) of the gene. DNA
damage caused by chemo- and radiotherapeutic agents
is thought to be repaired primarily by the short patch
repair [4]. The remaining SNP, rs3135974, located in
intron 3 of the LIG3 gene, amember of theDNA ligase
family that catalyzes the joining of DNA ends and is
involved in short patch repair [20], was associated with
increased risk of TRM and decreased risk disease re-
lapse. Although the biological relevance of rs3135974
is unknown, the association of rs3135974 with both
increased TRM risk and decreased disease relapse
supports the hypothesis that rs3135974 may decrease
BER activity. Lower BER activity would increase
damage to normal tissues, resulting in higher cell death
in normal tissues and increasing the risk of TRM. In
contrast, tumor cells with lower BER would not be
able to efficiently repair DNA damage because of
chemotherapeutic agents, leading to cell death and
decreasing risk of disease relapse. None of the 6 SNPs
found to be associated with TRM have been evaluated
in previous studies.
The association between 3 SNPs, rs167715,
rs3219463, and rs3219476, and TRM, found in
univariate analyses after adjustment for all clinical cova-
riates in a broad HCT population, was also observed
after restricting to ahomogenouspopulation (recipients
of HLA-identical sibling donor MA transplant).
Strengths of this study includehigh-quality genotyping,
(only SNPs that had a concordance rate of 95% or
greater using 61 pairs of blinded duplicate samples
were selected for further analysis) and use of an LD
tagSNP approach to comprehensively evaluate the as-
sociation between genetic variation in the base excision
repair pathway and treatment outcome after allogeneic
HCT. Limitations of this study include the lack
of information regarding the biological significance of
these SNPs and inability to examine somatic mutations
in BERgenes within tumor cells thatmay also influence
treatment outcomes following allogeneic HCT. To
control for multiple comparisons, we have used a strin-
gentP-value of#.01, butwe recognize that our findings
need to be validated in independent datasets. Finally,
TRM, itself includes several causes of death (after
excluding disease relapse). Limited sample size in this
study prevented subgroup analyses to evaluate the asso-
ciation of BER SNPs with individual causes of TRM.
This study provides support to the hypothesis that
common genetic variants in BER are likely associated
with outcomes after allogeneic HCT. If confirmed,
polymorphisms in BER genes can be used as genetic
biomarkers to identify groups of patients who would
be at high risk for TRM and disease relapse. Pretrans-plant conditioning regimens can then be modified in
these high-risk individuals to improve transplant
outcomes.
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